<DOC>
	<DOCNO>NCT00612638</DOCNO>
	<brief_summary>Objectives : To determine maximum tolerate dose CPT-11 administer follow Temodar plus O6-benzylguanine To characterize toxicity associate w combo CPT-11 + Temodar plus O6-BG To observe pt clinical antitumor response treat w combo CPT-11 + Temodar + O6-BG</brief_summary>
	<brief_title>Ph . I Temozolomide + O6-BG + Irinotecan Treatment Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas</brief_title>
	<detailed_description>Objectives study : determine maximum tolerate dose CPT-11 administer follow Temodar + O6-benzylguanine ( O6-BG ) ; characterize toxicity associate w combo CPT-11 + Temodar + O6-BG ; observe pt clinical antitumor response treat w combo CPT-11 + Temodar plus O6-BG . Pts histologically confirm diagnosis recurrent primary malignant glioma . 2 separate stratum accrue independently : Stratum 1-pts receive Dilantin , Tegretol/phenobarbital . Stratum 2-pts anti-convulsants Dilantin , Tegretol/phenobarbital/pts anti-convulsants . Each stratum treat &amp; escalate independent . Pre-chemo , O6-BG administer intravenously 120 mg/m2 , 1hr , prior administration Temodar day 1 21-day cycle . Post-chemo , O6-BG administer intravenously 30 mg/m2/day , 48hrs , immediately completion CPT-11 infusion day 1 21-day cycle . Temodar administer orally 355 mg/m2 , fast state , within 60 minute end 1hr O6-BG infusion . Treatment cycle may repeat every 3 week follow dose Temozolomide previous cycle . CPT-11 administer intravenously fast state 90min . CPT-11 infusion begin 1hr Temozolomide administration . Initial dose 60 mg/m2 stratum 1 &amp; 40 mg/m2 stratum 2 . Treatment cycle may repeat every 3 wks follow dose CPT-11 previous cycle . Major toxicity associate w CPT- 11 myelosuppression &amp; diarrhea . Temozolomide well tolerate adult &amp; child w common toxicity mild myelosuppression . Other , less likely , potential toxicity include nausea &amp; vomiting , constipation , headache , alopecia , rash , burn sensation skin , esophagitis , pain , diarrhea , lethargy , &amp; hepatotoxicity . Hypersensitivity reaction yet note w Temozolomide . As case w many anti-cancer drug , Temozolomide may carcinogenic . O6-BG toxicity include transient lymphopenia see w O6-BG single agent . O6-BG combo w agent could cause exacerbation adverse event currently know cause agent , / combo may result event never previously associate w either agent . Animal study indicate agitation , lethargy , convulsion , nausea , vomit , rapid heart rate , elevate liver function , leukopenia , lymphopenia could see .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Phenytoin</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<mesh_term>Convulsants</mesh_term>
	<criteria>Pts histologically confirm diagnosis recurrent primary malignant glioma Age &gt; 18yrs Evidence measurable recurrent/residual primary CNS neoplasm contrastenhanced MRI , unless medically contraindicate An interval &gt; 2 wks prior surgical resection/6 wks prior XRT/chemo , &amp; enrollment protocol , unless unequivocal evidence tumor progression surgery , XRT/chemo KPS &gt; 60 percent Adequate hematologic , renal &amp; liver function demonstrate lab value perform within 14 day , inclusive , prior administration chemo : ANC &gt; 1500/mm3 Platelet count &gt; 00,000/mm3 Hemoglobin &gt; 10gm/dL BUN &amp; serum creatinine &lt; 1.5 x ULN Total serum bilirubin &lt; 1.5 x ULN SGOT &amp; SGPT &lt; 2.5 x ULN Alkaline phosphatase &lt; 2 x ULN Pts must recover effect major surgery.= Pts must life expectancy &gt; 12wks Pts/legal guardian must give write , informed consent Pts require immediate XRT Pts recover surgery Pts neurologically stable 2wks prior study entry Pts poor medical risk nonmalignant systemic disease well w acute infection treat w intravenous antibiotic Frequent vomiting/medical condition could interfere w oral medication intake Previous active malignancy treat past year except localized insitu carcinoma &amp; basal/squamous cell carcinoma skin Known HIV positivity/AIDSrelated illness Pregnant/nursing woman Women childbearing potential use effective method contraception . Women childbearing potential must negative serum pregnancy test 24 hr prior administration study drug &amp; practice medically approve contraceptive precaution Men advise use effective method contraception Prior failure CPT11 Pts take immunosuppressive agent prescribed corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>O6-Benzylguanine</keyword>
	<keyword>O6-BG</keyword>
	<keyword>NSC 637037</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Recurrent cerebral anaplastic glioma</keyword>
	<keyword>Progressive cerebral anaplastic glioma</keyword>
	<keyword>Malignant glioma</keyword>
</DOC>